actinium pharmaceuticals, inc: redchip's global online ceo conference

Actinium Pharmaceuticals, Inc.

This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium

Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

No reliance may be placed for any purpose whatsoever on the information contained in these slides or presentation and/or opinions therein.

July 2014

Company Presentation

Ticker: ATNM (NYSE MKT)

2

Disclaimer and Safe Harbor Statement

Disclaimer

The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been approved

by an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation and its slides

for the purpose of engaging in investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.

This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any

securities in Actinium Pharmaceuticals, Inc. (“ATNM” or the “Company”) nor shall it or any part of it form the basis of or be relied on in

connection with any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information contained in

these slides or presentation and/or opinions therein. These slides and the presentation are exempt from the general restriction (in section 21 of the

Act) on the communication of invitations or inducements to engage in investment activity on the grounds that it is made to: (a) persons who have

professional experience in matters relating to investments who fall within Article 19(1) of the Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005 (the “Order”); or (b) high net worth entities and other persons to whom it may otherwise lawfully be communicated, falling

within Article 49(1) of the Order (all such persons together being referred to as “relevant persons”). Any person who is not a relevant person should

not rely on this presentation or any of its contents and all persons (whether relevant persons or otherwise) are recommended to seek their own

independent financial advice from a person authorized for the purposes of the Act before engaging in any investment activity involving the

Company’s securities.

Safe Harbor Statement

This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the private securities litigation

reform act of 1995. Such forward-looking information and statements are based on the current estimates and projections of the Company or

assumptions based on information currently available to the Company. Such statements involve known and unknown risks, uncertainties and other

factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including

changes from anticipated levels of revenues, future national or regional economic and competitive conditions, difficulties in developing the

Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s

products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are

reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-

looking information contained in this presentation. Any forward-looking statements or information in this presentation speak only as at the date of

this presentation.

3 This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium



Company Description

ACTINIUM is an oncology focused company with proprietary

alpha and beta emitter (radiation) technology initially targeting

early and late stage leukemia. We are one of only three companies

in the world developing alpha emitters.




Company Overview

♦ Overall investment of $100M to develop Alpha Emitter Technology to treat Leukemia

♦ 35 Patents (owned and in-licensed from Memorial Sloan-Kettering Cancer Center and others)

♦ Advisory Board Represents all Major Cancer Centers including Memorial Sloan-Kettering, Fred Hutchinson and MD Anderson

♦ Iomab-B on the cusp of entering Phase III for Relapsed and Refractory Acute Myeloid Leukemia (AML) (Patients > 55)




Company Overview (continued)

♦ Actimab-A in Phase I/II Trials for Newly Diagnosed AML

♦ 1 of only 3 Companies in World with Alpha Technology

♦ Fully Funded through Late 2015

♦ World Class Board of Directors

♦ Sloan-Kettering Largest Shareholder and also Merck a

Shareholder




Financial Facts

Actinium Pharmaceuticals

Stock Ticker ATNM

Stock Exchange NYSE MKT

Market Cap 188.4M

Average 3 Month Volume 134,406

Shares Outstanding 27.4M (40.0M fully diluted)

Float 21.1M

Cash as of Mar 31, 2014 5.9M

Cash from Financing 13.7M




Cancer Treatment Options

Treatment % 50% <10%

Pharmaceutical

Revenue %<3% ~30%

Always a pharmaceutical

Strong IP protection

Mostly proprietary

Monoclonal Antibodies (mAbs)Radiation

External radiation majority treatment

Internal radiation has mostly no IP

Commoditized

♦

♦

♦

♦

♦

♦

Antibody Approaches Targeting Cancer Cells

α

Cancer cell

β

Range

.06mm

Range

1 - 10mm

DNA




ATNM’s Proprietary Technology Platform

♦ Delivers radiation to cancer site via pharmaceutical carrier through an injection – Antibody provides precision, targeting cancer cells specifically while avoiding normal cells

– α emitters provide killing power with a very short range for narrow targeting

– β emitters kill by crossfire which is useful in select indications

* APIT is Actinium Pharmaceutical’s Alpha Particle Immunotherapy platform technology. It does not apply to Iomab-B.

** Certain β emitters, specifically iodine 131 in Iomab-B, do not require a linker.

APIT* Technology

Antibody (targeting agent)

Chelator (linker)

α / β** emitter (killing agent)




Clinically Relevant Emitters

* Clinically relevant but commercially not feasible in ATNM’s opinion.

* * Acquired by Bayer for this amount.

α emitterPlatform

PotentialHalf Life Stage IP Ownership

Market Cap

($mm)

Actinium 225 Yes 10 days Phase I/II Actinium Pharmaceuticals

Bismuth 213 Yes 46 minutes Phase II Actinium Pharmaceuticals

Radium 223 No 11 days Marketed Algeta

Thorium 227 Yes 18 days Preclinical Algeta

Astatine 211 * Yes 7 hours Phase II Duke University NM

Lead 212 * Yes 11 hours Phase I Areva Med NM

Bismuth 212 * Yes 1 hour Preclinical NM NM

$141

$1,601

$ 188

$2,900**




Robust Intellectual Property Protection

* DOTA is the name of the chelator (linker) that Actinium uses to attach the antibody to the α emitter.

Area Description US Expiration US Status Owner/Licensor

Platform Technology Metastases larger than 1 mm 2019 Issued MSKCC

Platform Technology Antibody conjugates with DOTA chelators;

methods of treating cancer using the same

2021 Issued MSKCC

Drug preparation methods Actinium 225 labeling method 2030 Pending Owned

Drug preparation methods Bismuth 213 labeling method 2019 Issued MSKCC

Isotope production methods Actinium 225 manufacturing in a cyclotron 2026/2027 Issued Owned

Monoclonal antibody composition and production Manufacturing of leukemia targeting antibody 2014 Issued Abbott Laboratories




ATNM’s Product Pipeline

s.d. – single dose

f.d. – fractionated dose (2)

1 HSCT stands for Hematopoietic Stem Cell Transplantation, a procedure in which cells capable of reconstituting normal bone marrow function are transplanted to a patient.

2 ATNM has decided to discontinue development of Bismab-A at this time due to supply, logistics and cost reasons. Actimab-A is the second generation drug of Bismab-A.

3 Properties of actinium 225 are uniquely suited for Antiangiogenesis and ATNM is considering options for further development in that area.

4 Glioblastoma (GBM) and breast cancer models are founded on an antiangiogenesis approach. Antiangiogenesis therapies starve cancerous tumors by choking off blood supplies to them.




Iomab-B: Next Step – Phase III Trial

♦ Experience with 250+ patients in 5 Phase I and II clinical trials

♦ In-licensed from Fred Hutchinson Cancer Center, 7 ongoing physician trials with BC8 mAb

♦ Indication is to condition bone marrow in relapsed and refractory AML patients over 55 years old

in preparation for HSCT

Iomab-B regimen Conventional Care

(high dose chemo followed by HSCT)

♦ Almost all patients eligible ♦ <10% eligible

♦ ~30% survive 1 year plus,

~20% survive 2 years plus

♦ <10% survive 1 year plus,

<2% survive 2 years plus

♦ Up to $200K per patient ♦ Up to $330K per patient

Treatment Options for Older Refractory AML Patients*

Survival:

Cost:

Treatment:

Usage:

*Source: Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 2012;97(12):1916-

1924. doi:10.3324/haematol.2012.066100

“Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease”, Dalia Mahmoud, MBA,

Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting abstract.




Iomab-B Phase I/II Results

♦ Only potential cure for blood cancers is HSCT, but vast majority of patients over 50 are ineligible

– Iomab-B has demonstrated ability to successfully prepare these patients for HSCT

♦ Clinical trials completed in 250+ patients with various incurable blood cancers

– In both PI and PII trials, Iomab-B led to effective treatment in patients with no other options left

All relapsed/refractory AML patients over 50 Rel/ref AML patients over 50 w/ poor cytogenetics

30%

19%

10%

0%

10%

0%0%

5%

10%

15%

20%

25%

30%

35%

1 year 2 years

Perc

en

tag

e S

urv

ival

Iomab-B HSCT (N=27)

Current HSCT (N=10)

Chemotherapy (N=61)

33%

16%

3%

0%

3%

0%0%

5%

10%

15%

20%

25%

30%

35%

1 year 2 years

Perc

en

tag

e S

urv

ival

Iomab-B HSCT (N=18)

Current HSCT (N=19)

Chemotherapy (N=95)

N = Number of patients treated;

Iomab-B results from FHCRC clinical trials;

Current HSCT and Chemotherapy results from MD Anderson outcomes analysis.




Iomab-B FDA Meeting Results

♦ A successful End of Phase II meeting was held with the FDA and

agreements were reached on the following

– Path to approval

– Number of studies

– Phase III trial design to support a BLA submission

– Patient population

– Study size (n)

– Primary and secondary endpoints

– Statistical considerations




Currently no approved treatments for Iomab-B targeted patients

Phase I and Phase II represent physician trials at Fred Hutchison Cancer Research Center. Phase III trials represent ATNM sponsorship.

Non-AML timelines are projections and the Company makes no representation as to their ability to meet these timelines.

Sources: “Current Uses and Outcomes of Hematopoetic Stem Cell Transplantation 2010”, CIMBTR Summary Slides;

“Trade, foreign policy, diplomacy and health: Pharmaceutical Industry”, WHO website, http://www.who.int/trade/glossry/story073/en/ ;

“Hematopoetic stem cell transplantation A Global Perspective”, NIH Public Access, JAMA 2010; Company Estimates

Iomab-B Development Plan

Indication* 2014 2015 2016 2017 2018 2019 2020 2021 2022

WW Mkt.

potential

Acute Myeloid Leukemia

$ 793

Myelodysplastic Syndrome

$ 264

Acute Lymphoblastic

Leukemia

$ 264

Non-Hodgkins Lymphoma

and Hodgkins disease

$ 1,455

Multiple Myeloma

$ 1,322

Total $ 4,098

III Sales start

III Sales start II I

Sales start II III

III Sales start II

Approval

Approval

Approval

III Sales start II I Approval

Approval

http://www.who.int/trade/glossry/story073/en/




Actimab-A vs. Current Treatments

Treatment:

Usage: ♦ 64% of patients 60+ use this

option due to lack of tolerable

alternatives

♦ 36% of patients 60+ are

eligible

♦ Potentially any AML patient

due to limited side effects

Survival: ♦ Less than 2 months ♦ Less than 6 months ♦ Limited history; Bismab-A

trials show median survival is

4x greater

Cost: ♦ $55K per patient ♦ $170K per patient ♦ $60K per patient

New Treatment Option

Supportive Care Actimab-AHigh Dose Chemotherapy

Current Treatment Options*

*Source: ARCH INTERN MED/Vol 162, July 22, 2002;

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease, Dalia Mahmoud,

MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc and Marja Hensen, MSc, 54th ASH Annual Meeting.




Target: ♦ AML ♦ AML

Effectiveness: ♦ Proof of concept in humans + 500x more potent than Bismab-A

Clinical Stage: ♦ Excellent results in Phase II ♦ Currently in a Phase I/II Trial

Supply Chain: ♦ Complex, high COGS + Simple, 10x lower COGS

Ease of Use: ♦ Complex on site preparation + Central manufacturing

♦ Does not require additional diagnostics ♦ Does not require additional diagnostics

Bismab-A Actimab-A

Actimab-A shows superior efficacy to Bismab-A in a comparable trial

* More than 5% of bone marrow blasts signifies persistent presence of leukemia cells.

Bismab-A Profile Actimab-A Advantages

1st Generation 2nd Generation APIT

Platform

Bismab-A experience implies successful Actimab-A trial results

Parameter Bismab-A Actimab-A

Elimination of peripheral blasts 27% 63%

Bone Marrow blasts decrease by 50% or more 28% 50%

Bone Marrow blasts 5% or less post treatment* 0% 20%




Actimab-A Clinical Trial Update

♦ Started the new multicenter Phase I/II clinical trial

♦ Expanded the number of participating clinical centers:

– Memorial Sloan-Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer

Center, University of Pennsylvania Health Center, MD Anderson Cancer Center

♦ New protocol sets lower standard than MSKCC PI Trial

– Treating newly diagnosed patients

– Introducing cytoreduction (reduces the number of cancer cells)

– New patient population is likely to respond better to treatment based on medically accepted criteria

– No toxicity outside of blood cells at doses expected to be clinically effective

♦ Targeting end of Phase II trial in 2015, preliminary data by ASH 2014

♦ No new AML drugs have been approved; unmet medical needs remain, which should

create interest from potential licensors, investors (Stemline, Marshall Edwards)




Market Positioning for Iomab-B, Actimab-A

Treatment Response Treatments Diagnosis

AML

Age >55

Complete

Response

Relapsed &

Refractory

AML

HSCT

Death

High dose

chemotherapy

Actimab-A Complete

Response

Death

Reduced Intensity

BM Conditioning

Reduced Intensity

BM Conditioning

Iomab-B

♦ HSCT is a procedure

that restores stem cells

destroyed by high doses

of chemotherapy and/or

radiation therapy

♦ HSCT is widely used in

other forms of cancer

outside of AML

♦ ATNM can leverage its

proprietary platform for

additional HSCT

indications

Negative Response

ATNM Pipeline Drugs

Positive Response

Current Treatments

ATNM products target both treatment stages for AML patients over 55 years of age




Market Potential of Product Pipeline

♦ The $1.3 billion Bone Marrow Transplant (BMT) market in

the US is largely unaddressed by novel pharmaceutical drug

companies

♦ BMT is the fastest growing hospital procedure in the US

– ~20,000 of the ~60,000 BMTs in 2010 were

performed in the US

♦ Sustained growth in patients treated over 55 yrs old

– 8% in 2000 to 21% in 2005 and 27% in 2007

♦ Acute Myeloid Leukemia is the deadliest form of

leukemia

– 55% of AML patients are over 65 years old

– Disease is worse in older people

– Insufficient treatment options are available in the

marketplace

– Treatment kills as many patients as it helps due to

toxicity

HSCT (Iomab-B) AML (Actimab-A)

1. Target market includes USA, EU and Japan

2. Market Potential calculated based on assumption that Actinium products for solid cancer indications will be priced at $20,000 per treatment;

HSCT preparation product will be priced at $85,000 per treatment; AML product will be priced at $60,000 per treatment; and GBM product

will be priced at $60,000 per treatment. Estimates based on independent third party research and adjusted for lower pricing in non-US

markets.

# Cancer Indication Cases/Yr. in

target market1

Target

Population

Worldwide Market

Potential ($mm)2

1st HSCT (Bone Marrow) 48,000 48,000 $4,100

2nd Acute Myeloid Leukemia (AML) 41,600 24,000 $920

3rd Glioblastoma Multiforme (GBM) 26,500 26,500 $1,100

4th Prostate Cancer (metastatic) 591,000 298,455 $5,959

5th Metastatic Colorectal Cancer 536,000 241,200 $4,824

Source: GLOBOCAN, SEER , and the Company




Recent Phase I/Phase II Cancer Licensing Deals

Company

Phase at

Signing

Deal

Size

Upfront

Fee Date Deal Description Algeta Phase II $800 $61 9/3/2009 Algeta signs $800 million deal with Bayer for

Alpharadin in prostate cancer bone metastases

Areva Med Phase I NA NA 7/27/2012 Areva Med signs agreement with Roche for an

alpha radio-immunotherapy platform (Lead-

212) in malignant cancer

Endocyte Phase II $1,000 $120 4/16/2012 Endocyte signs agreement with Merck for

Vintafolide (EC145)

Genmab Phase I/II $1,100 $55 8/30/2012 Genmab signs agreement with Johnson & Johnson

for Daratumumab in multiple myeloma

Innate Pharma Phase I $465 $35 7/6/2011 Innate Pharma signs agreement with Bristol-Myers

Squibb for AML antibody IPH2102

Medivation Phase II $765 $110 10/27/2009 Medivation signs agreement with Astellas Pharma

for MDV3100

Threshold Pharmaceuticals Phase II $592 $25 2/3/2012 Threshold Pharmaceuticals signs agreement with

Merck KGaA for TH-302 in AML and other

indications

Topotarget Phase II $350 $30 2/2/2010 TopoTarget signs agreement with Spectrum

Pharmaceuticals for Belinostat

All Figures in USD ($mm)

Rich deals available for novel technologies with proof of concept

Source: Medtrack, Company Reports.




Near-term Value Drivers

♦ Iomab-B

– Complete PIII Protocol

– Start cGMP mAb mfg

– Start drug mfg cGMP process

– Complete cGMP mAb mfg

– Complete Drug mfg cGMP

– Submit PIII IND

– Start PIII

♦ Actimab-A

– Complete PI trial

– Complete mfg. improvements

– Start and complete PII trial

♦ Third Program

– Start preclinical development

– Complete preclinical development

– File IND

Multiple development milestones in next 12-18 months as ATNM’s products advance

to a stage of development

Uplisting to NYSE MKT (Accomplished March 26, 2014)

♦ Additional Analyst Coverage

♦ Collaborations




Core Team & Advisors

Team Background

Kaushik J. Dave, PhD, MBA

President and CEO,

♦ 25 years of Pharma and Biotech industry at both big Pharma and small startups.

♦ Formerly, EVP at Antares Pharma Inc., VP at Palatin Technologies Inc., and Big Pharma (Schering-Plough and Merck)

♦ BPharm from University of Bath (UK), PhD from University of Kansas, MBA from Wharton School at The University of

Pennsylvania;

Gerri Henwood

Chief Development Officer

♦ President & Founder of Malvern Consulting Group and President & CEO of Recro Pharma

♦ Former Founder, President & CEO of Auxilium Pharmaceuticals, Inc (NASDAQ:AUXL)

♦ Former Founder & CEO of IBAH (formerly NASDAQ listed; acquired by Omnicare (NYSE))

♦ Board of Directors of Alkermes, Inc. (NASDAQ:ALKS), Garnet BioTherapeutics, Inc., LZ Therapeutics, Inc., and MAP

Pharmaceuticals, Inc.(NASDAQ:MAPP)

Dragan Cicic, MD, MBA

COO & CMO

♦ 9 years at Actinium Pharmaceuticals (ATNM), previously serving as Medical Director

♦ Formerly a strategic consultant at QED Technologies and an investment banker at SG Cowen Securities

♦ MBA, Wharton School at The University of Pennsylvania; MD, School of Medicine at The Belgrade University

♦ Nieman Fellow at Harvard University

Richard Steinhart BBA, MBA

Director

♦ Industry Consultant

♦ Formerly Senior Vice President, Finance and Chief Financial Officer of MELA Sciences Inc.

♦ Formerly Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and

management consulting firm focused on healthcare and technology companies.

♦ B.B.A. and M.B.A., Pace University

Sergio Traversa, PharmD, MBA

Director

♦ CEO of Relmada Therapeutics, Inc.

♦ 25+ years of management and investment experience in healthcare as a Portfolio Manager & Sr. Pharmaceutical Analyst (Mehta &

Isaly, ING Barings, Merlin BioMed & Rx Capital) and in industry (CNS at Eli Lilly, Pfizer)

♦ MBA, Finance at New York University, Laurea of Pharmacy at the University of Turin

David Nicholson, PhD

Director

♦ Head of R&D, Bayer CropScience

♦ Formerly Sr. VP and Head Worldwide Licensing and Knowledge Management at Merck

♦ Formerly Head of R&D at Organon prior to acquisition by Schering-Plough

♦ Ph.D., University of Wales

Sandesh Seth, MS, MBA

Chairman of the Board

♦ Head of Healthcare Investment Banking at Laidlaw & Company (UK) Ltd.

♦ 20+ years experience in investment banking (Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in

industry (Pfizer, Warner-Lambert, SmithKline)

♦ MBA, Finance at New York University; MS, Pharmaceutical Sciences at University of Oklahoma Health Center




Clinical Advisory Board

Treatment Center Advisory Board Members

Memorial Sloan Kettering

Cancer Center

David Scheinberg, M.D., PhD Chairman of Experimental Therapeutics at MSKCC

Vincent Astor Chair

Scientific Co-Founder

Fred Hutchinson

Cancer Center

Elihu H. Estey, M.D. Professor of Medicine

Division of Hematology

University of Washington School of Medicine

WHO Treatment guidelines for AML

John Pagel, M.D., PhD Assistant Professor/Assistant Member

Department of Medicine, Division of Oncology

Lead Investigator for Iomab-B

MD Anderson Cancer Center Hagop Kantarjian, M.D. Professor of Leukemia

Department Chair, Department of Leukemia

Division of Cancer Medicine

University of Texas

Key Investigator for Actimab-A

Johns Hopkins Medicine Richard Wahl, M.D. Director, Division of Nuclear Medicine/PET

Professor of Nuclear Medicine

Professor of Radiology and Oncology

Vice Chairman, Technology and New Business Development

Department of Radiology

“Father of PET Imaging”

Judith Karp, M.D. Professor of Oncology

Director, Adult Leukemia Program, Division of

Hematologic Malignancies

The Sidney Kimmel Comprehensive Cancer Center

Columbia University

Medical Center

Joseph G. Jurcic, M.D. Professor of Clinical Medicine

Director of Hematologic Malignancies

Hematology/Oncology Division

CAB Chairman, Lead Investigator for Actimab-A trials

University of Pennsylvania

Health System

Alexander Perl, M.D. Assistant Professor of Medicine

Division of Hematology/Oncology




Highlights

Prior clinical data for both Iomab-B and Actimab-A favor successful trial results

Breakthrough therapy potential implies successful market penetration for both Iomab-B and Actimab-A

APIT platform poised to deliver multiple blockbuster cancer drugs

An expert team possessing the vision and desire to enhance shareholder value

Positioned to benefit from increased market recognition of targeted payload therapies and an initial high-value, niche product model

Actinium Pharmaceuticals, Inc.

This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in Actinium



July 2014

Company Presentation

Ticker: ATNM (NYSE MKT)

actinium pharmaceuticals, inc: redchip's global online ceo conference

Health & Medicine